Top 10 Pharmaceutical Companies in india in 2019 [Updated] - Pharma Job Portal
Join Group Now Watch Job Videos

Tuesday, 26 November 2019

Top 10 Pharmaceutical Companies in india in 2019 [Updated]



Top 10 Pharmaceutical Companies in India 2019: 
India is among the leading global producer of cost-effective medicines and vaccines, supplying a total of 20% of the total global demand by volume.
Today, India is among the countries with an established domestic pharmaceutical industry, with a strong network of 3000 national and multinational drug companies and more than 10,500 manufacturing units.

The pharmaceutical sector in India was valued at US$ 33 billion in 2017 and contributes the second-largest share of pharmaceutical and biotech workforce in the world.
The ‘Pharma Vision 2020’ by the government’s department of pharmaceuticals aims to make India a major hub for end-to-end drug discovery.

India’s major generic drug producers like SUN PHARMA, Cipla, etc. hold a strong position in the global drug supply chain and play an integral role in developing and progressing the pharmaceutical industry.

India’s current Foreign Direct Investment (FDI) policy allows 100 percent FDI under automatic route in greenfield pharmaceutical projects and up to 100 percent FDI under government approval in brownfield projects.

As per the Economic Survey 2018-19, government expenditure (as a percentage of GDP) increased to 1.5 percent in 2018-19 from 1.2 percent in 2014-15 for health. Indian pharmaceutical sector is expected to grow at a CAGR of 15 percent soon and the medical device market expected to grow US$ 50 billion by 2025. FDI increased to 74 percent in existing pharmaceutical companies and 100 percent for new projects.

Medicine spending in India is projected to grow 9-12 percent by the next five years, leading India to become one of the top 10 countries in terms of medicine spending.

Going forward, better growth in domestic sales would also depend on the ability of the companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants and anti-cancers that are on the rise.

The Indian government is constantly taking several steps to reduce costs and bring down healthcare expenses and a measure to provide a healthy lifestyle to even poor people. The government is also focusing on the introduction of generic drugs into the market and is expected to benefit the Indian pharmaceutical companies.

List of Top 10 pharma companies in India 2019:

Here is the list of top 10 pharma companies in India 2019

  • Sun Pharmaceuticals Industries Limited
  • Cipla
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Limited
  • Lupin Limited
  • Glenmark Pharmaceuticals
  • Cadila Healthcare Limited
  • Torrent Pharmaceuticals Limited
  • Intas Pharmaceuticals Limited
  • Mankind Pharma Limited

Top 15 Pharma Companies in India by revenue



Sun Pharmaceuticals Industries Limited

SUN PHARMA is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra known for the manufacturing and selling of pharmaceutical formulations and active pharmaceutical ingredients (APIs).

The company was founded in the year 1983 by Dilip Sanghvi (now the Managing Director of Sun Pharma) in Vapi, Gujarat with five products to treat psychiatry ailments.

Today, the company’s major therapeutic areas including cardiology, psychiatry, neurology, gastroenterology, and diabetology. The company also provides Active Pharmaceutical Ingredients (APIs) such as warfarin as blood diluters, carbamazepine as anti-convulsant, etodolac as NSAID, and clorazepate as well as anti-cancers, steroids, peptides, sex hormones, and controlled substances.

After Acquiring RANBAXY in the year 2014, Sun Pharma became India’s top pharma company with a net worth of US$390 million (2019) and around 32, 000 employees (2019).

Sun Pharma has many other acquisitions and joint ventures with many foreign companies that proved to be the major milestones for the company’s development and success. This year company commercialized ILUMYA TM, YONSATM, and XELPROSTM in the US. CEQUATM is expected to be launched in the US in FY20.

The company is expecting to continue to build a global specialty pipeline with focused research and development (R&D) investments with its demerged arm SPARC. The principal focus areas for specialty portfolio include segments like dermatology, ophthalmology and oncology.

Cipla

Cipla was founded by Khwaja Abdul Hamied as ‘The Chemical, Industrial and Pharmaceutical Laboratories’ in 1935 in Mumbai. Cipla has a major sell of Active Pharmaceutical ingredients to other manufacturers for marketing. It also has a sell of pharmaceutical and personal care products, including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate.

The company is the world’s largest manufacturer of antiretroviral drugs and a therapy leader in India for anti-malarial with a market share of over 34%. The company manufactured the world’s first oral iron chelator with the name, Deferiprone in 1995.

Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries with around 26000 employees working in making Cipla one of the top pharmaceutical companies in India as well as in the world.

Cipla has a total net worth of US$4 billion with an increase of 4.83 % over the revenue. The company spends over 7.4% of its revenue on R&D activities.

The primary focus areas for R&D is the development of new formulations, drug-delivery systems, and APIs. The company also focuses on closely monitoring the repurposing and repositioning of existing drugs. The interesting area of research includes prodrugs, metabolites, liposomal drugs, Nano-particles and many more. The ultimate objective is to develop products for faster regulatory approvals in the niche market.

Aurobindo Pharma

Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC CITY, Hyderabad, India. The company was founded by P.V. Ramprasad Reddy and K. Nityanand Reddy in 1986 but commenced operations in 1988-89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry. Aurobindo Pharma has a key presence in therapeutic segments such as neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology, and cephalosporins.

The company has 2 manufacturing facilities worldwide with 22000+ employees globally. The company manufactured more than around 33 billion diverse dosage forms in 2018-19 making revenue of US$ 2.8 billion in 2018-19.

The company has launched 50 new products, including 12 injectables in the market in 2018-19.

Aurobindo Pharma plans to expand its product portfolio with high-value products in oncology, hormones biosimilars and novel drug delivery solutions like depot injections, inhalers, patches, and films.

The company focuses on scaling up to LEAP ahead where LEAP stands for Lead with a range of products; Expand into new areas; Attaining capabilities and strengthening compliance; Promote an execution-oriented growth mindset.

Dr. Reddy’s Laboratories Limited

Dr. Reddy’s was founded in 1984 by Anji Reddy in Hyderabad, Telangana, India. The company began as a supplier to Indian Drug manufacturers. In 1987, Reddy's launched Norilet, the company’s first recognized brand in India. Reddy’s also became the first Indian company to export the active ingredients for pharmaceuticals to Europe.

The company had a total revenue of US$2.1 billion in 2017-18. Around 22000 employees work worldwide for Dr.Reddy’s Pharma.

The atop active pharmaceutical ingredients from Dr.Reddy’s Pharma include ranitidine, losartan, clopidogrel, Ramipril, atorvastatin, and many others.

In 1992, Reddy’s formed a joint venture with Biomed, the biggest pharmaceutical producer in Russia.

Reddy’s also involved in targeting specialty generics products in western markets to create a foundation for drug discovery. In 1992, Dr.Reddy’s research foundation was established in order to do research in the area of new drug discovery. Reddy’s research thrust focuses on large niche areas in western markets – anti-cancer, anti-diabetics, cardiovascular and anti-infection drugs.

Lupin Limited

Headquartered in Mumbai, Maharashtra, India, Lupin Limited is a multinational pharmaceutical company founded by Desh Bandhu Gupta in the year 1968.

The company is a significant player in key therapy areas such as pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis from which collected total revenue of INR 155.77 billion in 2018-19. Lupin stands 1st in the anti-TB segment globally. Around 50000 employees work globally for the company’s progress and development.

The company’s research program covers the entire pharma product chain. Lupin’s R&D covers generics research, process research, pharmaceutical research, ADDS research, intellectual property management, Novel Drug Discovery and Development, and biotechnology research.

In FY 2019, the company launched 22 new products in the US market. The company launched Solosec® successfully in the US and started women's health specialty business in full intensity. The company also launched the first orphan drug - NaMuscla® in the UK, Germany, and France.

The company also focuses on social responsibility and thus, has a foundation under the name The Lupin Human Welfare and Research Foundation (LHWRF).

In FY 2020, Lupin is planning to bring its first biosimilar to market, commercialize its first inhalation product in the US and launch an injectables portfolio.

Glenmark Pharmaceuticals

Glenmark is a pharmaceutical company headquartered in Mumbai, India that was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer. The company primarily focused on new drugs and biosimilars in the fields of cancer dermatology and respiratory diseases. Glenmark is a leading player in the discovery of new molecules both NCEs (New Chemical Entity) and NBEs (New Biological Entity).

Glenmark also entered the exclusive licensing agreement with Australia’s Sequirus to commercialize its nasal spray Ryaltris (a fixed those combinations of antihistamine and a steroid) for the treatment of seasonal allergic rhinitis (SAR).

The company has 17 manufacturing facilities globally and 5 R&D centers in India and Switzerland with gross revenue of INR 91 billion. The company has over 12,000 dedicated employees worldwide.

Cadila Healthcare Limited

Cadila Healthcare Limited is a well-known research-oriented, a technology-driven pharmaceutical company headquartered at Ahmedabad, Gujarat which focuses on research areas of biotechnology, formulations and Active Pharmaceutical Ingredients (API).

The company was founded in 1952 by Ramanbhai Patel, formerly a lecturer in the L.M. College of Pharmacy. It evolved over the next four decades into an established pharmaceutical company. In June 2007, the company acquired Nikkho as part of Zydus Healthcare Brasil Ltd. In 2015, the company acquired another Indian pharmaceutical company called German Remedies.

Cadila Healthcare Limited provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients (APIs) and animal healthcare products to wellness products.

Cadila Healthcare Limited is India’s sixth-largest pharmaceutical company based on overall revenue. In FY 2019, the company’s revenue was INR 131 billion which saw an increase of 10% y-o-y revenue in FY 2018.

Company has 9 production operations in India which develop and manufactures a large range of pharmaceutical as well as diagnostics, herbal products, skincare products, and other OTC products. The company also produces the generics for hepatitis C treatment i.e. sofosbuvir as SoviHep. Injectable ketorolac tromethamine is manufactured by Zydus Cadila for the microbial growth. The company is ranked among the top three players in the promoted covered market of gynecology, dermatology, respiratory, pain management, cardiovascular and gastrointestinal therapeutic areas.

Torrent Pharmaceuticals Limited

Headquartered in Ahmedabad, Torrent Pharmaceuticals Ltd. It is the flagship company of the Torrent Group. Promoted by U.N. Mehta.

The company operates in more than 40 countries having a number of employees of around 14000 with total revenue of INR 7673 Cr in 2019. Torrent Pharma is active in the therapeutic areas of Cardiovascular, CNS, Gastro-intestinal, diabetology, anti-infective and pain management segments. The key products include calcium Carbonate along with Vitamin D3, Losartan, Rosuvastatin.

The company in 2017 has completed the acquisition of the branded business of Unichem Laboratories Limited. Brand building is its key priority and currently, 19 brands (Shelcal is among the top one) features amongst the top 500 brands.

The company is developing several in-house new chemical entities in the areas of metabolic, cardiovascular, gastrointestinal, dermatological and respiratory disorders. The most advanced discovery program of the company is the NCE for the reduction of cardiovascular risk. The next advanced discovery program is for the management of heart failure in diabetic patients.

Given the future market moving towards complex products, Torrent is ramping up is a pipeline with products like oral liquids, ophthalmic, ointments & creams, and oncology.

Intas Pharmaceuticals Limited

Intas Pharmaceutical Limited set up in 1984 by Binnish Chudgar was formerly an independent biotechnology company and was known as Intas biopharmaceuticals ltd. Headquartered in Ahmedabad, the company is the leading biosimilar product manufacturers in Asia.

Intas has 13 commercialized biosimilars including Docetaxel and Paclitaxel. As on date, Intas continues its R&D efforts in chronic disease areas such as oncology, rheumatology, auto-immune, nephrology, ophthalmology, and plasma-derived product based therapies. Intas has 14 formulation manufacturing facilities of which seven are located in India, and the rest in U.K. and Mexico.

In FY 2018, the company’s revenue was INR 108 billion with an overall growth of 29.84% over last year’s revenue.

Intas is currently investing in a higher barrier to entry developments such as biosimilar and new chemical entities and is set to continue raising the bar of healthcare excellence globally in the near future.

Mankind Pharma Limited

Mankind Pharma Limited was founded in 1995 by R.C. Juneja and Rajeev Juneja based at New Delhi.

The company has products in therapeutic areas ranging from antibiotics to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.

The company has a revenue of more than INR 52 billion with over 14000 employees working together for the company’s growth and development.

The company focuses mainly on chronic segments/lifestyle diseases and that generates long-term prescriptions. It also focuses on the OTC division where it has leading brands like Manforce, Preganews, Acnestar, Gasofast, Unwanted 72.

Conclusion
This was the list of India based Top 10 pharmaceutical companies in India based on the y-o-y revenue. There are many more other top companies like Biocon Limited, Piramal Enterprises Limited, Wockhardt Limited, Divis Laboratories Limited, Abbott India Limited and many more.

This article is written by
Authur,
Mariya Ibrahim Bootwala
If you want to submit your article in pharma job portal, please mail us at pharmajobportal@gmail.com

Recent Pharma Jobs this week

Popular